<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11679954</article-id><article-id pub-id-type="doi">10.3390/ph17121583</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-17-01583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Berbamine Promotes the Repair of Lower Limb Muscle Damage in Chronic Limb-Threatening Ischemia by Inhibiting Local Inflammation and NF-&#x003ba;B Nuclear Translocation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Lei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-pharmaceuticals-17-01583" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Biao</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-pharmaceuticals-17-01583" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-1696-5259</contrib-id><name><surname>Zhang</surname><given-names>Zhenxi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-pharmaceuticals-17-01583" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yutong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af1-pharmaceuticals-17-01583" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yingying</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-pharmaceuticals-17-01583" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Jing</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceuticals-17-01583" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Qiao</surname><given-names>Tong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceuticals-17-01583" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-17-01583" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Gavriilaki</surname><given-names>Eleni</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Hsu</surname><given-names>Tsai-Ching</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-17-01583"><label>1</label>Department of Vascular Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Zhongshan Road 321, Nanjing 210008, China; <email>df21350078@smail.nju.edu.cn</email> (L.Z.); <email>622023350106@smail.nju.edu.cn</email> (B.Z.); <email>602023350088@smail.nju.edu.cn</email> (Z.Z.); <email>dg1935015@smail.nju.edu.cn</email> (Y.L.); <email>dg1735039@smail.nju.edu.cn</email> (J.C.)</aff><aff id="af2-pharmaceuticals-17-01583"><label>2</label>Department of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Zhongshan Road 321, Nanjing 210008, China; <email>mf20350076@smail.nju.edu.cn</email></aff><author-notes><corresp id="c1-pharmaceuticals-17-01583"><label>*</label>Correspondence: <email>qiaotongmail@nju.edu.cn</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>17</volume><issue>12</issue><elocation-id>1583</elocation-id><history><date date-type="received"><day>25</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives</bold>: Chronic Limb-Threatening Ischemia (CLTI) is a chronic limb ischemic disease caused by vascular lesions, characterized by pain, ulcers, and gangrene, which can be life-threatening in severe cases. The objective of this study is to explore whether Berbamine (BBM) can protect against and repair ischemic muscle tissue in the lower limbs; <bold>Methods</bold>: Using a mouse hindlimb ischemia (HLI) model, 36 C57BL6 mice were divided into sham, HLI, and HLI+BBM treatment groups. <bold>Results</bold>: Our findings indicate that BBM can restore motor function and muscle tissue pathology in mice, potentially by inhibiting the nuclear translocation of nuclear factor kappa-B (NF-&#x003ba;B), thereby alleviating tissue inflammation caused by chronic ischemia, reducing muscle cell apoptosis, inhibiting M1 macrophage polarization, and promoting angiogenesis. <bold>Conclusions</bold>: Our research suggests that BBM has the potential to protect against ischemic damage in lower limb muscle tissue, providing a new approach to the treatment of CLTI.</p></abstract><kwd-group><kwd>berbamine</kwd><kwd>limb ischemia</kwd><kwd>inflammation</kwd><kwd>nuclear factor kappa-B</kwd><kwd>apoptosis</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>818870348</award-id><award-id>82200543</award-id></award-group><award-group><funding-source>Medical Research Project of Jiangsu Provincial Health Commission</funding-source><award-id>ZD2021056</award-id></award-group><funding-statement>This research was funded by the National Natural Science Foundation of China (818870348, 82200543), and the Medical Research Project of Jiangsu Provincial Health Commission (ZD2021056).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-17-01583"><title>1. Introduction</title><p>Chronic Limb-Threatening Ischemia (CLTI) is a severe vascular disease primarily characterized by inadequate blood flow to the lower limbs, leading to symptoms such as pain, ulcers, and gangrene [<xref rid="B1-pharmaceuticals-17-01583" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-17-01583" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-17-01583" ref-type="bibr">3</xref>]. Currently, approximately 40 million people worldwide are afflicted with CLTI, and the incidence rate is rising annually due to factors such as population aging and the increasing prevalence of chronic diseases like diabetes [<xref rid="B1-pharmaceuticals-17-01583" ref-type="bibr">1</xref>]. Therefore, delving into the pathogenesis of CLTI and searching for effective treatment methods have become significant research topics in modern medicine.</p><p>The primary treatment objectives include promoting arteriogenesis or angiogenesis, correcting the pathological changes in ischemic leg muscles, and limiting the progression of atherosclerotic thrombosis in the arteries supplying the lower limbs, as well as surgical interventions [<xref rid="B4-pharmaceuticals-17-01583" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-17-01583" ref-type="bibr">5</xref>]. Berbamine (BBM) is a natural compound extracted from the traditional Chinese medicine <italic toggle="yes">Berberis amurensis</italic> and possesses a variety of biological activities [<xref rid="B6-pharmaceuticals-17-01583" ref-type="bibr">6</xref>]. It has the function of inhibiting Ca<sup>2+</sup>/calmodulin-dependent protein kinase II &#x003b3; (CaMKII &#x003b3;) and nuclear factor kappa-B (NF-&#x003ba;B) [<xref rid="B7-pharmaceuticals-17-01583" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceuticals-17-01583" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-17-01583" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-17-01583" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-17-01583" ref-type="bibr">11</xref>]. Previous studies have found that BBM has potential therapeutic effects on prostate cancer [<xref rid="B8-pharmaceuticals-17-01583" ref-type="bibr">8</xref>], colon cancer [<xref rid="B12-pharmaceuticals-17-01583" ref-type="bibr">12</xref>], and leukemia [<xref rid="B10-pharmaceuticals-17-01583" ref-type="bibr">10</xref>] by inhibiting the NF-&#x003ba;B signaling pathway. Additionally, it shows therapeutic value in non-cancerous diseases such as liver injury [<xref rid="B13-pharmaceuticals-17-01583" ref-type="bibr">13</xref>], diabetes [<xref rid="B14-pharmaceuticals-17-01583" ref-type="bibr">14</xref>], and ischemia&#x02013;reperfusion injury in the heart and brain [<xref rid="B15-pharmaceuticals-17-01583" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-17-01583" ref-type="bibr">16</xref>]. BBM also has the ability to alleviate bone loss caused by excessive osteoclast activity [<xref rid="B17-pharmaceuticals-17-01583" ref-type="bibr">17</xref>]. The NF-&#x003ba;B signaling pathway is markedly elevated in the muscle tissue of patients suffering from peripheral arterial disease (PAD), correlating strongly with inflammation induced by ischemia [<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>]. Hence, we hypothesize that BBM could be employed to treat muscle lesions in patients with PAD.</p><p>In our study, we constructed a classical hindlimb ischemia model. This was completed in adult male C57BL/6 mice. Our goal was to investigate whether BBM could play a potential protective role in hindlimb ischemia. Additionally, we aimed to illustrate its pathophysiological and pharmacological mechanisms.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-17-01583"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-17-01583"><title>2.1. BBM Improves Hind Limb Ischemia in Mice by Enhancing Motor Function and Skeletal Muscle Regeneration</title><p>To investigate whether BBM could mitigate the hind limb muscle damage induced by ischemia, we obtained muscle samples from sham mice and from mice with hind limb ischemia that were administered BBM for analysis. Hematoxylin and eosin (HE) staining demonstrated that the muscle cross-sectional area distribution and average cross-sectional area were substantially increased in the BBM-treated group (<xref rid="pharmaceuticals-17-01583-f001" ref-type="fig">Figure 1</xref>a,b). Ischemic skeletal muscle tissue is characterized by glycogen depletion, and Periodic Acid&#x02013;Schiff (PAS) staining revealed that hind limb ischemia resulted in a significant reduction in muscle glycogen, which was notably attenuated by BBM treatment (<xref rid="pharmaceuticals-17-01583-f001" ref-type="fig">Figure 1</xref>c,d). Muscle regeneration is compromised when the number or function of muscle satellite cells is abnormal, leading to the replacement of muscle fibers with ectopic tissues such as fat and fibrous tissue [<xref rid="B19-pharmaceuticals-17-01583" ref-type="bibr">19</xref>]. To evaluate the extent of fat and fibrous tissue deposition in ischemic skeletal muscle, we performed oil red O staining (<xref rid="pharmaceuticals-17-01583-f001" ref-type="fig">Figure 1</xref>e,f) and Masson staining (<xref rid="pharmaceuticals-17-01583-f001" ref-type="fig">Figure 1</xref>g,h) on sections of ischemic gastrocnemius muscle. Our research indicates that BBM effectively reduces the accumulation of lipids and collagen in muscle tissue affected by hind limb ischemia. Through endurance running experiments, we found that BBM significantly enhanced the exercise endurance of mice (<xref rid="pharmaceuticals-17-01583-f001" ref-type="fig">Figure 1</xref>i). These findings suggest that BBM can markedly improve the reduced motor function and skeletal muscle damage associated with hind limb ischemia in mice.</p></sec><sec id="sec2dot2-pharmaceuticals-17-01583"><title>2.2. BBM Promotes Angiogenesis in the Ischemic Hind Limbs of Mice</title><p>Angiogenesis is a vital compensatory mechanism in response to limb ischemia and a key process in the repair of ischemic damage. To assess the impact of BBM on vascular distribution in the ischemic hind limbs, we employed CD31 immunohistochemistry and observed that BBM markedly increased the formation of new blood vessels in the ischemic hind limbs (<xref rid="pharmaceuticals-17-01583-f002" ref-type="fig">Figure 2</xref>a,b). Furthermore, qPCR analysis revealed that BBM upregulated the expression of <italic toggle="yes">Vascular Endothelial Growth Factor A</italic> (<italic toggle="yes">VEGFA</italic>) at the transcriptional level in the context of hind limb ischemia (<xref rid="pharmaceuticals-17-01583-f002" ref-type="fig">Figure 2</xref>c). By collecting the culture supernatant from peritoneal macrophages cultured in a hypoxia chamber and applying it to HUVECs, we found that the angiogenic potential of HUVECs was significantly enhanced in the BBM-treated group (<xref rid="pharmaceuticals-17-01583-f002" ref-type="fig">Figure 2</xref>d&#x02013;g). The HUVECs in the BBM-treated group exhibited significantly higher proliferation and angiogenic capabilities compared to the control group. The restoration of skeletal muscle damage relies on the activation, proliferation, and myogenic differentiation of muscle satellite cells. These findings suggest that BBM promotes angiogenesis and enhances blood circulation in the ischemic hind limbs.</p></sec><sec id="sec2dot3-pharmaceuticals-17-01583"><title>2.3. BBM Inhibits M1 Polarization of Macrophages in the Ischemic Hind Limbs of Mice</title><p>Inflammation is closely associated with the development and progression of PAD and is related to poor prognosis in PAD patients [<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>,<xref rid="B20-pharmaceuticals-17-01583" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-17-01583" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-17-01583" ref-type="bibr">22</xref>]. By inhibiting M1 macrophage polarization, the secretion of inflammatory factors by macrophages can be suppressed [<xref rid="B23-pharmaceuticals-17-01583" ref-type="bibr">23</xref>]. To examine whether BBM could inhibit the polarization of M1-type macrophages induced by hindlimb ischemia, we performed qPCR experiments. The findings revealed that BBM significantly decreased the mRNA expression levels of <italic toggle="yes">iNOS</italic> and <italic toggle="yes">IL-6</italic>, which are indicative of M1 macrophage polarization, while it increased the mRNA expression of <italic toggle="yes">IL-10</italic> and <italic toggle="yes">Arg1</italic>, markers associated with M2-type macrophage polarization (<xref rid="pharmaceuticals-17-01583-f003" ref-type="fig">Figure 3</xref>a). Immunofluorescence staining also demonstrated that the expression of CD86, a marker for M1 macrophages, was notably enhanced in the muscles of mice with hind limb ischemia, and this increase was markedly suppressed by BBM treatment (<xref rid="pharmaceuticals-17-01583-f003" ref-type="fig">Figure 3</xref>b,c). Additionally, the expression of CD163, a marker for M2 macrophages, was significantly elevated in the muscle tissue of the BBM-treated group (<xref rid="pharmaceuticals-17-01583-f003" ref-type="fig">Figure 3</xref>d,e). Through qPCR analysis, we also observed a significant increase in the mRNA levels of the inflammation-related genes Tnf-&#x003b1; and Il-1&#x003b2; (<xref rid="pharmaceuticals-17-01583-f003" ref-type="fig">Figure 3</xref>f). These results indicate that BBM can inhibit M1 macrophage polarization and promote the shift towards an M2 phenotype, thereby dampening inflammation and fostering angiogenesis in the ischemic hind limbs of mice.</p></sec><sec id="sec2dot4-pharmaceuticals-17-01583"><title>2.4. BBM Inhibits Apoptosis Induced by Hindlimb Ischemia in Mice</title><p>Apoptosis-related genes are significantly upregulated in the lower limb muscle tissue of PAD patients [<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>]. NF-&#x003ba;B possesses dual functions: it can both promote tissue inflammation, thereby exacerbating apoptosis, and facilitate the survival of tissue cells. However, NF-&#x003ba;B may play a more significant role in chronic inflammation resulting from ischemia and hypoxia. To assess whether BBM could inhibit the impact of hind limb ischemia on muscle tissue apoptosis in mice, we conducted TUNEL staining. The TUNEL staining revealed a substantial increase in the percentage of apoptotic cells within the ischemic muscle tissue, which was attenuated by BBM treatment (<xref rid="pharmaceuticals-17-01583-f004" ref-type="fig">Figure 4</xref>a,b). Subsequently, we investigated the expression of apoptosis-related proteins via Western blot analysis. We observed a significant upregulation of caspase-3 and cleaved PARP1 in the hind limb ischemia model, and BBM significantly decreased the expression of these proteins in the ischemic muscle (<xref rid="pharmaceuticals-17-01583-f004" ref-type="fig">Figure 4</xref>c,d). These findings suggest that BBM can reduce the apoptosis of muscle tissue induced by hind limb ischemia.</p></sec><sec id="sec2dot5-pharmaceuticals-17-01583"><title>2.5. BBM Inhibits NF-&#x003ba;B Nuclear Translocation</title><p>Previous studies have found that the NF-&#x003ba;B signaling pathway is significantly upregulated in PAD tissues [<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>]. Furthermore, research has demonstrated that BBM can down-regulate IKK&#x003b1; and p-I&#x003ba;B&#x003b1;, subsequently inhibiting the nuclear translocation of NF-&#x003ba;B, which results in reduced expression of NF-&#x003ba;B downstream targets [<xref rid="B7-pharmaceuticals-17-01583" ref-type="bibr">7</xref>,<xref rid="B10-pharmaceuticals-17-01583" ref-type="bibr">10</xref>]. Moreover, the activation of the NF-&#x003ba;B signaling pathway is a crucial transcription factor that facilitates M1 polarization in macrophages [<xref rid="B24-pharmaceuticals-17-01583" ref-type="bibr">24</xref>]. NF-&#x003ba;B activation is mediated by its translocation into the nucleus, where it acts as a transcription factor. Initially, through immunofluorescence detection, we discovered that BBM can inhibit the nuclear translocation of NF-&#x003ba;B induced by hypoxia and ischemia in HLI tissue (<xref rid="pharmaceuticals-17-01583-f005" ref-type="fig">Figure 5</xref>a,b). After isolating nuclear and cytoplasmic proteins separately and performing Western blot analysis, we observed a notable increase in the nuclear content of NF-&#x003ba;B protein within the ischemic tissue, and BBM was found to decrease the nuclear NF-&#x003ba;B protein levels (<xref rid="pharmaceuticals-17-01583-f005" ref-type="fig">Figure 5</xref>c,d). These findings suggest that BBM protects against lower limb ischemia by suppressing the nuclear translocation of NF-&#x003ba;B.</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-17-01583"><title>3. Discussion</title><p>In this study, we discovered that BBM can rectify muscle tissue damage induced by hind limb ischemia by inhibiting the nuclear translocation of NF-&#x003ba;B. The primary research objectives of this paper encompass: (1) establishing that BBM can alleviate muscle damage caused by hind limb ischemia in mice; (2) demonstrating that BBM treatment reduces inflammation and apoptosis while promoting angiogenesis in muscle tissue impacted by hind limb ischemia; and (3) revealing that the anti-inflammatory mechanism of BBM is linked to its suppression of NF-&#x003ba;B nuclear translocation.</p><p>PAD is caused by factors such as atherosclerosis, leading to insufficient blood supply to the distal limbs. The main symptoms are lower limb pain, numbness, weakness, etc. Early symptoms include intermittent claudication, while late symptoms include ischemic rest pain, limb-end ischemic necrosis, ulcers, and gangrene, which may eventually lead to amputation or threaten life, a condition known as CLTI [<xref rid="B1-pharmaceuticals-17-01583" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-17-01583" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-17-01583" ref-type="bibr">3</xref>]. The main pathology of PAD includes microvascular dysfunction and a decrease in muscle volume and density [<xref rid="B2-pharmaceuticals-17-01583" ref-type="bibr">2</xref>]. In addition to surgical revascularization, the current main treatment methods for PAD include Cilostazol, lipid-lowering medications, and exercise therapy [<xref rid="B2-pharmaceuticals-17-01583" ref-type="bibr">2</xref>]. In this study, we confirmed the protective effect of BBM on hind limb ischemic injury, which is derived from its anti-inflammatory properties. The mechanism of action may be closely related to the inhibition of NF-&#x003ba;B activation.</p><p>Previous transcriptomic sequencing studies have found that the NF-&#x003ba;B signaling pathway is significantly activated in the ischemic muscle tissue of the lower limbs [<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>]. NF-&#x003ba;B is a family of inducible transcription factors that regulate a series of immune responses [<xref rid="B24-pharmaceuticals-17-01583" ref-type="bibr">24</xref>]. BBM is recognized as a natural inhibitor of NF-&#x003ba;B. Previous research has indicated that BBM can treat leukemia by inhibiting the phosphorylation of CaMKII &#x003b3;, which subsequently prevents the nuclear translocation of NF-&#x003ba;B [<xref rid="B10-pharmaceuticals-17-01583" ref-type="bibr">10</xref>]. Beyond its impact on leukemia, BBM also mitigates liver damage, inhibits osteoclast differentiation, and represses breast cancer growth by targeting the NF-&#x003ba;B signaling pathway [<xref rid="B13-pharmaceuticals-17-01583" ref-type="bibr">13</xref>,<xref rid="B17-pharmaceuticals-17-01583" ref-type="bibr">17</xref>,<xref rid="B25-pharmaceuticals-17-01583" ref-type="bibr">25</xref>]. In this study, we found that BBM can inhibit the increase in NF-&#x003ba;B expression induced by ischemic hind limbs, thereby alleviating tissue inflammation.</p><p>Inflammation plays a significant role in the development and progression of peripheral arterial disease [<xref rid="B2-pharmaceuticals-17-01583" ref-type="bibr">2</xref>,<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>,<xref rid="B21-pharmaceuticals-17-01583" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-17-01583" ref-type="bibr">22</xref>,<xref rid="B26-pharmaceuticals-17-01583" ref-type="bibr">26</xref>]. The expression of NF-&#x003ba;B, IL-1, and TNF-&#x003b1; signaling pathways is significantly increased in the lower limb muscles of PAD patients [<xref rid="B18-pharmaceuticals-17-01583" ref-type="bibr">18</xref>]. Macrophage M1 phenotype is a pro-inflammatory phenotype, and M1 macrophages secrete a large number of inflammatory factors, promoting local tissue inflammatory response [<xref rid="B23-pharmaceuticals-17-01583" ref-type="bibr">23</xref>]. Activation of the NF-&#x003ba;B signaling pathway promotes the polarization of macrophages to the M1 phenotype [<xref rid="B27-pharmaceuticals-17-01583" ref-type="bibr">27</xref>]. In this study, we found that BBM can inhibit the activation of the NF-&#x003ba;B signaling pathway in the ischemic hind limb muscle tissue, suppress the polarization of macrophages to the M1 phenotype, and decrease the expression level of inflammatory molecules in the tissue. Additionally, an increase in M2-like macrophages enhances VEGFA secretion, fostering angiogenesis and aiding in the repair of ischemic tissue. These results suggest that BBM alleviates tissue inflammation induced by hind limb ischemia by inhibiting the NF-&#x003ba;B signaling pathway.</p></sec><sec id="sec4-pharmaceuticals-17-01583"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-17-01583"><title>4.1. Preparation of Berbamine</title><p>BBM, sourced from MCE (Shanghai, China), was verified to have a purity exceeding 99%. It was prepared for experimental use by dissolving in 1% dimethyl sulfoxide and then further diluting with Phosphate-Buffered Saline (PBS). The dosage of BBM was determined in line with findings from previous research [<xref rid="B13-pharmaceuticals-17-01583" ref-type="bibr">13</xref>].</p></sec><sec id="sec4dot2-pharmaceuticals-17-01583"><title>4.2. Animals</title><p>Adult male C57BL/6 mice, aged 8 weeks and weighing 25.0 &#x000b1; 3.0 g, were provided with sterile water and standard rodent chow. These mice were housed in pathogen-free cages supplied by the Model Animal Research Center at Nanjing University. All experimental procedures were conducted in accordance with the guidelines set forth by the Animal Investigation Ethics Committee of Nanjing University and adhered to the regulations outlined in the National Institutes of Health (NIH Publication No. 85&#x02013;23, revised 1996).</p></sec><sec id="sec4dot3-pharmaceuticals-17-01583"><title>4.3. Hindlimb Ischemia Model</title><p>In this study, 8-week-old male C57BL/6J mice were subjected to a surgical procedure involving the ligation and transection of the unilateral hind limb femoral artery. The mice were fasted for 8 h preoperatively, and the anesthetic dosage was determined based on their body weight. Anesthesia was administered via an intraperitoneal injection of tribromoethanol at a concentration of 250 mg/kg. The mice were positioned supine on a sterile surgical board and secured with medical tape. The surgical area was then sterilized using iodophors. A longitudinal incision of about 1 cm was made along the blood vessel&#x02019;s path from the inguinal region to the inner thigh. With the aid of a dissecting microscope, the femoral artery sheath was dissected bluntly, and a suture was placed underneath the sheath for subsequent use. The membranous vascular sheath was carefully punctured with micro-forceps to reveal the femoral artery, femoral vein, and their branches. The femoral artery was then isolated and manipulated using micro-forceps. It was ligated and transected at both the proximal and distal ends with 7&#x02013;0 surgical sutures. The skin was closed with sutures, and the mouse was placed on a warming pad to recover from the anesthesia. We provided postoperative analgesics: Buprenorphine (0.1 mg/kg body weight, every 8 h) for 2 days.</p></sec><sec id="sec4dot4-pharmaceuticals-17-01583"><title>4.4. Drug Treatments and Experimental Design</title><p>A total of 36 mice were randomly allocated into 3 groups, with 12 mice in each group: the Sham group, the hindlimb ischemia group, and two ischemia + BBM groups receiving 30 mg/kg of BBM. Mice in the ischemia and ischemia + BBM groups underwent hindlimb ischemia, whereas those in the Sham group did not. After the onset of hindlimb ischemia, mice in the ischemia + BBM groups were administered daily oral gavage of BBM. Twenty-one days later, the mice were euthanized using carbon dioxide, and the muscle tissues were then preserved in an environmental-friendly GD muscle fixative solution for subsequent histological evaluation. Muscle homogenates were utilized to measure the expression levels of specific proteins. Muscle tissue samples from the gastrocnemius muscle were harvested and stored at &#x02212;80 &#x000b0;C for subsequent analysis.</p></sec><sec id="sec4dot5-pharmaceuticals-17-01583"><title>4.5. Histological Evaluation</title><p>Samples were immersed in environmentally friendly GD muscle fixative solution and stored at 4 &#x000b0;C for 48 h. Transverse and longitudinal sections, each 3 &#x003bc;m thick, were sliced from the embedded tissue blocks using a microtome. These sections were then subjected to staining with hematoxylin and eosin to assess inflammatory infiltration and interstitial edema.</p></sec><sec id="sec4dot6-pharmaceuticals-17-01583"><title>4.6. TUNEL Staining</title><p>The TUNEL assay is utilized to detect DNA fragmentation by marking the 3&#x02032;-hydroxyl ends of double-stranded DNA breaks that occur during apoptosis. It is a common technique for identifying and quantifying apoptotic cells. Following the preparation of tissue samples, which involved paraffin embedding and fixation with paraformaldehyde, staining was carried out using a Cell Apoptosis Detection Kit from Servicebio (Wuhan, China). The number of TUNEL-positive cells was then analyzed using ImageJ software (1.54k).</p></sec><sec id="sec4dot7-pharmaceuticals-17-01583"><title>4.7. Immunofluorescence (IF) Assays and Immunohistochemical (IHC) Staining</title><p>For IF staining, tissue sections were initially dewaxed and subjected to antigen retrieval and BSA blocking. They were then incubated with the primary antibody, p65 (Proteintech, 10745-1-AP, 1:1000; Manchester, UK), CD86 (Abcam, ab239075, 1:100; Cambridge, UK), CD163 (Proteintech, 16646-1-AP, 1:250) overnight at 4 &#x000b0;C. Afterward, the sections underwent three washes with PBS. Subsequently, the sections were incubated with a fluorophore-conjugated secondary antibody at room temperature for 1h. DNA was stained with DAPI for visualization. Representative areas were imaged using a laser-scanning confocal microscope.</p><p>For IHC staining, tissue sections were used to stain CD31 (1:500, Cat 550274) and the secondary antibodies from Santa Cruz Biotech (Santa Cruz, 1:200; Shanghai, China). Images were captured under a light microscope (Zeiss, Jena, Germany). The intensity of positive staining was analyzed by ImageJ software.</p></sec><sec id="sec4dot8-pharmaceuticals-17-01583"><title>4.8. Preparation of Cytoplasmic and Nuclear Proteins and Western Blot Analysis</title><p>Cytoplasmic and nuclear extracts were prepared using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime, Shanghai, China) following the manufacturer&#x02019;s instructions. Cytoplasmic and nuclear proteins were used for Western blot analysis.</p><p>Mouse tissues were homogenized and lysed with RIPA lysis buffer (Beyotime, Shanghai, China). Protein concentration was determined using Bradford buffer. Total protein (20&#x02013;40 &#x000b5;g/lane) was separated on SDS&#x02013;PAGE gels and transferred to nitrocellulose membranes. The membranes were blocked with 5% non-fat milk and incubated with primary and secondary antibodies for protein detection. The target bands were detected with the following antibodies: anti-cleaved caspase-3 (Proteintech, 68773-1-Ig, 1:1000), anti-cleaved PARP1 (Hubio, SU0314, 1:1000; Toronto, ON, Canada), anti-p65 (Proteintech, 10745-1-AP, 1:1000), anti-&#x003b2;-Actin (Bioworld, AP0060, 1:10,000; St. Helier, UK), anti-Gapdh (Biodragon, B1030, 1:1000; Szcz&#x00119;sne, Poland), and anti-Histone 3 (Abcam, ab1791, 1:2000). The blots were then incubated with HRP-conjugated secondary antibodies (anti-rabbit or mouse). Protein bands were visualized using enhanced chemiluminescence detection reagents. Relative changes in protein expression were calculated from the mean pixel density using ImageJ and normalized to &#x003b2;-Actin or Gapdh.</p></sec><sec id="sec4dot9-pharmaceuticals-17-01583"><title>4.9. Quantitative Real-Time PCR</title><p>Total RNA was extracted from tissues or cells using the RNAiso Total RNA Extraction Reagent from Vazyme (Nanjing, China), following the manufacturer&#x02019;s instructions. Reverse transcription was carried out using the HiScript II 1st Strand cDNA Synthesis Kit from Vazyme, Nanjing, China. qPCR analysis was performed with the ChamQ Universal SYBR qPCR Master Mix from Vazyme, Nanjing, China, on the Applied Biosystems 7300 instrument. &#x003b2;-actin expression served as the endogenous control. The 2<sup>&#x02212;&#x00394;&#x00394;CT</sup> method was employed to analyze relative fold changes. The primer sequences used were as follows: for &#x003b2;-Actin, forward 5&#x02032;-GCCACTGCCGCATCCTCTTC-3&#x02032; and reverse 5&#x02032;-AGCCTCAGGGCATCGGAACC-3&#x02032;; for il10, forward 5&#x02032;-GCATGGCCCAGAAATCAAGG-3&#x02032; and reverse 5&#x02032;-AATCGATGACAGCGCCTCAG-3&#x02032;; for Asc, forward 5&#x02032;-TGCTTAGAGACATGGGCTTAC-3&#x02032; and reverse 5&#x02032;-CTGTCCTTCAGTCAGCACACT-3&#x02032;; for Caspase-1, forward 5&#x02032;-GACAAGGCACGGGACCTATGT-3&#x02032; and reverse 5&#x02032;-CAGTCAGTCCTGGAAATGTGC-3&#x02032;; for IL-18, forward 5&#x02032;-GACTCTTGCGTCAACTTCAAGG-3&#x02032; and reverse 5&#x02032;-CAGGCTGTCTTTTGTCAACGA-3&#x02032;; for IL-1&#x003b2;, forward 5&#x02032;-CAGGCAGGCAGTATCACTCA-3&#x02032; and reverse 5&#x02032;-AGGCCACAGGTATTTTGTCG-3&#x02032;; for Tnf-&#x003b1;, forward 5&#x02032;-ACGGCATGGATCTCAAAGAC-3&#x02032; and reverse 5&#x02032;-GGTCACTGTCCCAGCATCTT-3&#x02032;; and for VEGFA, forward 5&#x02032;-GGCTCTTCTCGCTCCGTAGT-3&#x02032; and reverse 5&#x02032;-TCACCGCCTTGGCTTGTCAC-3&#x02032;.</p></sec><sec id="sec4dot10-pharmaceuticals-17-01583"><title>4.10. Isolation of Peritoneal Macrophages</title><p>To isolate peritoneal macrophages, mice were injected intraperitoneally with 4% starch broth (comprising NaCl 0.5 g, beef extract 0.3 g, peptone 1.0 g, and starch 3.0 g in 100 mL of distilled water) three days prior to euthanasia. Following anesthesia, the abdominal skin was carefully incised by 1 cm, and 5&#x02013;8 mL of PBS containing 3% FBS was injected into the peritoneal cavity. After massaging for 10 min, the extract was centrifuged at 400&#x000d7; <italic toggle="yes">g</italic> for 5 min. Subsequently, the sediment was plated onto culture dishes containing complete medium. After the cells had adhered, the supernatant was collected 24 h after treatment with BBM 10 &#x003bc;&#x0039c; or DMSO in a hypoxic environment.</p></sec><sec id="sec4dot11-pharmaceuticals-17-01583"><title>4.11. Angiogenesis Assay</title><p>Human umbilical vein endothelial cells (HUVECs) were purchased from Guangzhou Cellcook Company, accompanied by a STR analysis report. Dulbecco&#x02019;s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum was obtained from Gibco, London, UK. After being treated with the conditioned medium obtained from the peritoneal macrophages as described above for 48 h, the HUVECs were subjected to subsequent experiments. The day before the experiment, the matrigel was placed in an ice box and stored in a 4 &#x000b0;C refrigerator to slowly thaw overnight. Note: prepare 4 &#x000b0;C pre-cooled pipette tips for aspirating the matrigel and a 96-well cell culture plate. Keep the matrigel in the ice box, add 50&#x02013;100 &#x003bc;L of matrigel to each well of the 96-well plate, aspirate slowly, and add it to the wall to avoid bubble formation. Each well of the 96-well plate was then inoculated with 50 &#x003bc;L of HUVECs at a density of 6000&#x02013;80,000 cells per well. Be careful not to puncture the matrigel with the pipette tip. Gently shake the culture plate to ensure even distribution of the cells, and then place it in a 37 &#x000b0;C-cell culture incubator. Typically, 6&#x02013;8 h later, distinct tubular structures can be observed. Images were captured using a microscope and analyzed with Image J software.</p></sec><sec id="sec4dot12-pharmaceuticals-17-01583"><title>4.12. Edu Assay</title><p>The Edu assay is based on the incorporation of EdU (5-ethynyl-2&#x02032;-deoxyuridine), a thymidine analog, during DNA synthesis, followed by a click reaction that labels EdU with Alexa Fluor 594 for detection. The HUVECs treated with the conditioned medium as previously described were subjected to the Edu assay using the Edu detection kit (Beyotime, Shanghai, China), following the specific experimental procedure. Images were captured using a fluorescence microscope and analyzed with Image J software.</p></sec><sec id="sec4dot13-pharmaceuticals-17-01583"><title>4.13. Statistics</title><p>All data are expressed as mean &#x000b1; SEM. Statistical analysis was conducted using one-way analysis of variance (ANOVA), followed by Tukey&#x02019;s multiple comparisons test, with GraphPad Prism 8.4.2 software. A <italic toggle="yes">p</italic> value less than 0.05 was deemed statistically significant. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-17-01583"><title>5. Conclusions</title><p>In summary, our findings suggest that BBM exerts a protective effect against hindlimb injury in mice. The underlying mechanism may be intimately linked to the inhibition of NF-&#x003ba;B-mediated inflammation. Consequently, these results suggest that BBM&#x02019;s protective role in this hindlimb model is significant, and it may alleviate clinical symptoms in patients by inhibiting chronic inflammation caused by lower limb ischemia. However, further clinical trials are needed to confirm these findings.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, L.Z. and T.Q.; methodology, L.Z. and B.Z.; software, L.Z.; validation, Z.Z., Y.L. and Y.Z.; formal analysis, L.Z.; investigation, L.Z.; resources, T.Q.; data curation, Z.Z., Y.L., Y.Z. and J.C.; writing&#x02014;original draft preparation, L.Z.; writing&#x02014;review and editing, J.C.; visualization, L.Z.; supervision, J.C.; project administration, J.C. and T.Q.; funding acquisition, J.C. and T.Q. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki, and approved by the Animal Investigation Ethics Committee of Nanjing University, approval number: 2024AE01037, date: 19 September 2024.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-17-01583"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Conte</surname><given-names>M.S.</given-names></name>
<name><surname>Bradbury</surname><given-names>A.W.</given-names></name>
<name><surname>Kolh</surname><given-names>P.</given-names></name>
<name><surname>White</surname><given-names>J.V.</given-names></name>
<name><surname>Dick</surname><given-names>F.</given-names></name>
<name><surname>Fitridge</surname><given-names>R.</given-names></name>
<name><surname>Mills</surname><given-names>J.L.</given-names></name>
<name><surname>Ricco</surname><given-names>J.B.</given-names></name>
<name><surname>Suresh</surname><given-names>K.R.</given-names></name>
<name><surname>Murad</surname><given-names>M.H.</given-names></name>
<etal/>
</person-group><article-title>Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia</article-title><source>Eur. J. Vasc. Endovasc. Surg.</source><year>2019</year><volume>58</volume><fpage>S1</fpage><lpage>S109.e33</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2019.05.006</pub-id><pub-id pub-id-type="pmid">31182334</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-17-01583"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Golledge</surname><given-names>J.</given-names></name>
</person-group><article-title>Update on the pathophysiology and medical treatment of peripheral artery disease</article-title><source>Nat. Rev. Cardiol.</source><year>2022</year><volume>19</volume><fpage>456</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1038/s41569-021-00663-9</pub-id><pub-id pub-id-type="pmid">34997200</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-17-01583"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farber</surname><given-names>A.</given-names></name>
<name><surname>Menard</surname><given-names>M.T.</given-names></name>
<name><surname>Conte</surname><given-names>M.S.</given-names></name>
<name><surname>Kaufman</surname><given-names>J.A.</given-names></name>
<name><surname>Powell</surname><given-names>R.J.</given-names></name>
<name><surname>Choudhry</surname><given-names>N.K.</given-names></name>
<name><surname>Hamza</surname><given-names>T.H.</given-names></name>
<name><surname>Assmann</surname><given-names>S.F.</given-names></name>
<name><surname>Creager</surname><given-names>M.A.</given-names></name>
<name><surname>Cziraky</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>2305</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2207899</pub-id><pub-id pub-id-type="pmid">36342173</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-17-01583"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furubeppu</surname><given-names>H.</given-names></name>
<name><surname>Ito</surname><given-names>T.</given-names></name>
<name><surname>Kakuuchi</surname><given-names>M.</given-names></name>
<name><surname>Yasuda</surname><given-names>T.</given-names></name>
<name><surname>Kamikokuryo</surname><given-names>C.</given-names></name>
<name><surname>Yamada</surname><given-names>S.</given-names></name>
<name><surname>Maruyama</surname><given-names>I.</given-names></name>
<name><surname>Kakihana</surname><given-names>Y.</given-names></name>
</person-group><article-title>Differential Regulation of Damage-Associated Molecular Pattern Release in a Mouse Model of Skeletal Muscle Ischemia/Reperfusion Injury</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>628822</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.628822</pub-id><pub-id pub-id-type="pmid">34381442</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-17-01583"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bihari</surname><given-names>A.</given-names></name>
<name><surname>Cepinskas</surname><given-names>G.</given-names></name>
<name><surname>Forbes</surname><given-names>T.L.</given-names></name>
<name><surname>Potter</surname><given-names>R.F.</given-names></name>
<name><surname>Lawendy</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Systemic application of carbon monoxide-releasing molecule 3 protects skeletal muscle from ischemia-reperfusion injury</article-title><source>J. Vasc. Surg.</source><year>2017</year><volume>66</volume><fpage>1864</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2016.11.065</pub-id><pub-id pub-id-type="pmid">28216347</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-17-01583"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schiff</surname><given-names>P.L.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Bisbenzylisoquinoline Alkaloids</article-title><source>J. Nat. Prod.</source><year>1991</year><volume>54</volume><fpage>645</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1021/np50075a001</pub-id><pub-id pub-id-type="pmid">1955879</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-17-01583"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>R.Z.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Zhao</surname><given-names>X.Y.</given-names></name>
</person-group><article-title>Berbamine, a novel nuclear factor kappa B inhibitor, inhibits growth and induces apoptosis in human myeloma cells</article-title><source>Acta Pharmacol. Sin.</source><year>2009</year><volume>30</volume><fpage>1659</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1038/aps.2009.167</pub-id><pub-id pub-id-type="pmid">19960011</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-17-01583"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group><article-title>Berbamine Inhibits the Biological Activities of Prostate Cancer Cells by Modulating the ROS/NF-&#x003ba;B Axis</article-title><source>Anticancer Agents Med. Chem.</source><year>2023</year><volume>23</volume><fpage>1626</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.2174/1871520623666230503094540</pub-id><pub-id pub-id-type="pmid">37638593</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-17-01583"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Luo</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Feng</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Berbamine reduces body weight via suppression of small GTPase Rab8a activity and activation of paraventricular hypothalamic neurons in obese mice</article-title><source>Eur. J. Pharmacol.</source><year>2022</year><volume>916</volume><fpage>174679</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174679</pub-id><pub-id pub-id-type="pmid">34982965</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-17-01583"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Meng</surname><given-names>Z.</given-names></name>
<name><surname>Gan</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Lou</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Gan</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>CaMKII &#x003b3;, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>4829</fpage><lpage>4839</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-06-434894</pub-id><pub-id pub-id-type="pmid">23074277</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-17-01583"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ling</surname><given-names>H.</given-names></name>
<name><surname>Gray</surname><given-names>C.B.</given-names></name>
<name><surname>Zambon</surname><given-names>A.C.</given-names></name>
<name><surname>Grimm</surname><given-names>M.</given-names></name>
<name><surname>Gu</surname><given-names>Y.</given-names></name>
<name><surname>Dalton</surname><given-names>N.</given-names></name>
<name><surname>Purcell</surname><given-names>N.H.</given-names></name>
<name><surname>Peterson</surname><given-names>K.</given-names></name>
<name><surname>Brown</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Ca<sup>2+</sup>/Calmodulin-dependent protein kinase II &#x003b4; mediates myocardial ischemia/reperfusion injury through nuclear factor-&#x003ba;B</article-title><source>Circ. Res.</source><year>2013</year><volume>112</volume><fpage>935</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.276915</pub-id><pub-id pub-id-type="pmid">23388157</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-17-01583"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Liang</surname><given-names>D.</given-names></name>
<name><surname>Zheng</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>M.</given-names></name>
<name><surname>Lv</surname><given-names>R.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>N.</given-names></name>
</person-group><article-title>Berbamine dihydrochloride suppresses the progression of colorectal cancer via RTKs/Akt axis</article-title><source>J. Ethnopharmacol.</source><year>2023</year><volume>303</volume><fpage>116025</fpage><pub-id pub-id-type="doi">10.1016/j.jep.2022.116025</pub-id><pub-id pub-id-type="pmid">36496042</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-17-01583"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kathem</surname><given-names>S.H.</given-names></name>
<name><surname>Abdulsahib</surname><given-names>W.K.</given-names></name>
<name><surname>Zalzala</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Berbamine and thymoquinone exert protective effects against immune-mediated liver injury via NF-&#x003ba;B dependent pathway</article-title><source>Front. Vet. Sci.</source><year>2022</year><volume>9</volume><elocation-id>960981</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2022.960981</pub-id><pub-id pub-id-type="pmid">35958317</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-17-01583"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J.-y.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<name><surname>Jia</surname><given-names>W.</given-names></name>
</person-group><article-title>Effects and mechanisms of berberine in diabetes treatment</article-title><source>Acta Pharm. Sin. B</source><year>2012</year><volume>2</volume><fpage>327</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2012.06.003</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-17-01583"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J.R.</given-names></name>
<name><surname>Lu</surname><given-names>H.D.</given-names></name>
<name><surname>Guo</surname><given-names>C.</given-names></name>
<name><surname>Fang</surname><given-names>W.R.</given-names></name>
<name><surname>Zhao</surname><given-names>H.D.</given-names></name>
<name><surname>Zhou</surname><given-names>J.S.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.L.</given-names></name>
<name><surname>Li</surname><given-names>Y.M.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.D.</given-names></name>
<etal/>
</person-group><article-title>Berberine attenuates ischemia-reperfusion injury through inhibiting HMGB1 release and NF-&#x003ba;B nuclear translocation</article-title><source>Acta Pharmacol. Sin.</source><year>2018</year><volume>39</volume><fpage>1706</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1038/s41401-018-0160-1</pub-id><pub-id pub-id-type="pmid">30266998</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-17-01583"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Gu</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Tan</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>H.T.</given-names></name>
</person-group><article-title>Berbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagy</article-title><source>Cell Death Dis.</source><year>2017</year><volume>8</volume><fpage>e2577</fpage><pub-id pub-id-type="doi">10.1038/cddis.2017.7</pub-id><pub-id pub-id-type="pmid">28151484</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-17-01583"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>G.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Lu</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
</person-group><article-title>Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>1032866</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.1032866</pub-id><pub-id pub-id-type="pmid">36408260</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-17-01583"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrucci</surname><given-names>L.</given-names></name>
<name><surname>Candia</surname><given-names>J.</given-names></name>
<name><surname>Ubaida-Mohien</surname><given-names>C.</given-names></name>
<name><surname>Lyashkov</surname><given-names>A.</given-names></name>
<name><surname>Banskota</surname><given-names>N.</given-names></name>
<name><surname>Leeuwenburgh</surname><given-names>C.</given-names></name>
<name><surname>Wohlgemuth</surname><given-names>S.</given-names></name>
<name><surname>Guralnik</surname><given-names>J.M.</given-names></name>
<name><surname>Kaileh</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Transcriptomic and Proteomic of Gastrocnemius Muscle in Peripheral Artery Disease</article-title><source>Circ. Res.</source><year>2023</year><volume>132</volume><fpage>1428</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.322325</pub-id><pub-id pub-id-type="pmid">37154037</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-17-01583"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sciorati</surname><given-names>C.</given-names></name>
<name><surname>Clementi</surname><given-names>E.</given-names></name>
<name><surname>Manfredi</surname><given-names>A.A.</given-names></name>
<name><surname>Rovere-Querini</surname><given-names>P.</given-names></name>
</person-group><article-title>Fat deposition and accumulation in the damaged and inflamed skeletal muscle: Cellular and molecular players</article-title><source>Cell. Mol. Life Sci.</source><year>2015</year><volume>72</volume><fpage>2135</fpage><lpage>2156</lpage><pub-id pub-id-type="doi">10.1007/s00018-015-1857-7</pub-id><pub-id pub-id-type="pmid">25854633</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-17-01583"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Signorelli</surname><given-names>S.S.</given-names></name>
<name><surname>Katsiki</surname><given-names>N.</given-names></name>
</person-group><article-title>Oxidative Stress and Inflammation: Their Role in the Pathogenesis of Peripheral Artery Disease with or Without Type 2 Diabetes Mellitus</article-title><source>Curr. Vasc. Pharmacol.</source><year>2018</year><volume>16</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.2174/1570161115666170731165121</pub-id><pub-id pub-id-type="pmid">28762307</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-17-01583"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>J.</given-names></name>
<name><surname>Carneiro</surname><given-names>A.</given-names></name>
<name><surname>Vila</surname><given-names>I.</given-names></name>
<name><surname>Silva</surname><given-names>C.</given-names></name>
<name><surname>Cunha</surname><given-names>C.</given-names></name>
<name><surname>Longatto-Filho</surname><given-names>A.</given-names></name>
<name><surname>Mesquita</surname><given-names>A.</given-names></name>
<name><surname>Cotter</surname><given-names>J.</given-names></name>
<name><surname>Mansilha</surname><given-names>A.</given-names></name>
<name><surname>Correia-Neves</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Inflammation and Loss of Skeletal Muscle Mass in Chronic Limb Threatening Ischemia</article-title><source>Ann. Vasc. Surg.</source><year>2023</year><volume>88</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2022.07.009</pub-id><pub-id pub-id-type="pmid">35926785</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-17-01583"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>J.</given-names></name>
<name><surname>Roque</surname><given-names>S.</given-names></name>
<name><surname>Lima Carneiro</surname><given-names>A.</given-names></name>
<name><surname>Longatto-Filho</surname><given-names>A.</given-names></name>
<name><surname>Vila</surname><given-names>I.N.</given-names></name>
<name><surname>Cunha</surname><given-names>C.</given-names></name>
<name><surname>Silva</surname><given-names>C.</given-names></name>
<name><surname>Mesquita</surname><given-names>A.</given-names></name>
<name><surname>Cotter</surname><given-names>J.</given-names></name>
<name><surname>Correia-Neves</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Reversion of the Inflammatory Markers in Patients With Chronic Limb-Threatening Ischemia</article-title><source>J. Am. Heart Assoc.</source><year>2024</year><volume>13</volume><fpage>e031922</fpage><pub-id pub-id-type="doi">10.1161/JAHA.123.031922</pub-id><pub-id pub-id-type="pmid">38606780</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-17-01583"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Liang</surname><given-names>H.</given-names></name>
<name><surname>Zen</surname><given-names>K.</given-names></name>
</person-group><article-title>Molecular mechanisms that influence the macrophage m1-m2 polarization balance</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><elocation-id>614</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00614</pub-id><pub-id pub-id-type="pmid">25506346</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-17-01583"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Joo</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>S.-C.</given-names></name>
</person-group><article-title>NF-&#x003ba;B signaling in inflammation</article-title><source>Signal Transduct. Target. Ther.</source><year>2017</year><volume>2</volume><fpage>17023</fpage><pub-id pub-id-type="doi">10.1038/sigtrans.2017.23</pub-id><pub-id pub-id-type="pmid">29158945</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-17-01583"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Luan</surname><given-names>J.</given-names></name>
<name><surname>Duan</surname><given-names>H.</given-names></name>
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Suppression of growth, migration and invasion of highly-metastatic hum an breast cancer cells by berbamine and its molecular mechanisms of action</article-title><source>Mol. Cancer</source><year>2009</year><volume>8</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-8-81</pub-id><pub-id pub-id-type="pmid">19796390</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-17-01583"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Signorelli</surname><given-names>S.S.</given-names></name>
<name><surname>Fiore</surname><given-names>V.</given-names></name>
<name><surname>Malaponte</surname><given-names>G.</given-names></name>
</person-group><article-title>Inflammation and peripheral arterial disease: The value of circulating biomarkers (Review)</article-title><source>Int. J. Mol. Med.</source><year>2014</year><volume>33</volume><fpage>777</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2014.1657</pub-id><pub-id pub-id-type="pmid">24535646</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-17-01583"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>S.</given-names></name>
<name><surname>Sanjo</surname><given-names>H.</given-names></name>
<name><surname>Takeda</surname><given-names>K.</given-names></name>
<name><surname>Ninomiya-Tsuji</surname><given-names>J.</given-names></name>
<name><surname>Yamamoto</surname><given-names>M.</given-names></name>
<name><surname>Kawai</surname><given-names>T.</given-names></name>
<name><surname>Matsumoto</surname><given-names>K.</given-names></name>
<name><surname>Takeuchi</surname><given-names>O.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
</person-group><article-title>Essential function for the kinase TAK1 in innate and adaptive immune responses</article-title><source>Nat. Immunol.</source><year>2005</year><volume>6</volume><fpage>1087</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1038/ni1255</pub-id><pub-id pub-id-type="pmid">16186825</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-17-01583-f001"><label>Figure 1</label><caption><p>BBM enhances motor function and ameliorates muscle tissue pathology in mice with hindlimb ischemia (HLI). (<bold>a</bold>) Representative images of gastrocnemius muscles, measured by H&#x00026;E staining (transverse section). (<bold>b</bold>) Quantification of the mean cross-sectional area of skeletal muscle HE staining, n = 8 per group. (<bold>c</bold>,<bold>d</bold>) Representative images of PAS staining and quantification of gastrocnemius muscles, transverse section, n = 8 per group. (<bold>e</bold>,<bold>f</bold>) Representative images of oil red O staining and quantification of gastrocnemius muscles, transverse section, n = 8 per group. (<bold>g</bold>,<bold>h</bold>) Representative images of Masson staining and quantification of gastrocnemius muscles, transverse section, n = 8 per group. (<bold>i</bold>) The endurance running distance of mice in each group over a fixed time, n = 8 per group. Data are expressed as mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceuticals-17-01583-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01583-f002"><label>Figure 2</label><caption><p>BBM promotes angiogenesis and skeletal muscle regeneration in the ischemic hind limbs of mice. (<bold>a</bold>,<bold>b</bold>) Representative immunohistochemistry images and quantification of CD31 in gastrocnemius muscles transverse sections, n = 8 per group. (<bold>c</bold>) The mRNA expression of <italic toggle="yes">VEGFA</italic> in gastrocnemius muscles examined by qPCR, n = 3 per group. (<bold>d</bold>,<bold>e</bold>) Representative immunofluorescence images and quantification of Edu in HUVECs, n = 3 per group. (<bold>f</bold>,<bold>g</bold>) Representative images and quantification of relative tube length and number of junctions in angiogenesis test, n = 3 per group. Data are expressed as mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="pharmaceuticals-17-01583-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01583-f003"><label>Figure 3</label><caption><p>BBM inhibits M1 polarization of macrophages and inflammation in the ischemic hind limbs of mice. (<bold>a</bold>) The mRNA expression of <italic toggle="yes">iNOS</italic>, <italic toggle="yes">IL-6</italic>, <italic toggle="yes">IL-10</italic>, and <italic toggle="yes">Arg1</italic> in gastrocnemius muscles examined by qPCR, n = 3 per group. (<bold>b</bold>,<bold>c</bold>) Representative immunofluorescence images and quantification of CD86 in gastrocnemius muscles transverse sections, n = 8 per group. (<bold>d</bold>,<bold>e</bold>) Representative immunofluorescence images and quantification of CD163 in gastrocnemius muscles transverse sections, n = 8 per group. (<bold>f</bold>) mRNA expression level of <italic toggle="yes">IL-1&#x003b2;</italic> and <italic toggle="yes">TNF-&#x003b1;</italic> in the gastrocnemius muscles of mice, detected by qPCR, n = 3 per group. Data are expressed as mean &#x000b1; SEM. * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001; ns: not significant.</p></caption><graphic xlink:href="pharmaceuticals-17-01583-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01583-f004"><label>Figure 4</label><caption><p>BBM inhibits apoptosis induced by hind limb ischemia in mice. (<bold>a</bold>,<bold>b</bold>) Representative immunofluorescence images and quantification of Tunel staining in gastrocnemius muscles transverse sections, n = 8 per group. (<bold>c</bold>,<bold>d</bold>) Representative immunoblot bands and quantitative analysis of cleaved-Caspase-3 and cleaved-Parp1 in gastrocnemius muscles, n = 3 per group. Data are expressed as mean &#x000b1; SEM. **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceuticals-17-01583-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-17-01583-f005"><label>Figure 5</label><caption><p>Berbamine inhibits NF-&#x003ba;B nuclear translocation. (<bold>a</bold>,<bold>b</bold>) nuclear translocation was determined by immunofluorescence staining for p65 (red) and DAPI staining for DNA (blue), n = 8 per group. (<bold>c</bold>,<bold>d</bold>) Nuclear p65 protein expression in gastrocnemius muscles was analyzed by western blot, n = 3 per group. Data are expressed as mean &#x000b1; SEM. **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="pharmaceuticals-17-01583-g005" position="float"/></fig></floats-group></article>